Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Extensive knowledge of pharmaceutical industry data sources including IQVIA Rx data (xPonent, xPonent Plantrak, DDD, and HCOS) or Symphony Rx data (Prescriber, Prescriber/Payer, PHAST), Patient Claims data, Patient Longitudinal data or other types of patient and physician level data.